Individualizing therapy for neovascular age-related macular degeneration with aflibercept
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2018
Price : $35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms VITAL
- 22 May 2018 Status changed from active, no longer recruiting to completed.
- 06 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 11 Feb 2016 Accrual to date is 96% according to United Kingdom Clinical Research Network record.